TG Therapeutics Executive Compensation
TG Therapeutics is a publicly traded company in the Healthcare sector.
Named Executive Officers — FY2023
Compensation Analysis
Computed directly from SEC-sourced figures tracked on this page — not a general description.
TG Therapeutics discloses FY2023 compensation for 2 named executive officers, totaling $17.7M. Michael S. Weiss, the Executive Officer, accounts for 89% of that combined total.
Cash compensation (salary plus bonus) made up 7% of TG Therapeutics's FY2023 tracked executive pay, with stock awards accounting for 85%. That's notably more stock-weighted than the typical Healthcare company in this dataset, where stock awards average 0% of tracked pay.
Among 78 other Healthcare companies in this dataset, TG Therapeutics's combined tracked executive pay of $17.7M ranks in the 62th percentile (industry median: $12.5M). Its highest-paid executive, Michael S. Weiss, ranks in the 74th percentile for top-executive pay in the sector (industry median: $6.0M).